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Introduction
During early mammalian development embryos possess the 
capacity to produce complete female and male reproductive 
tracts. The Müllerian ducts will become the upper third of 
the vagina, the cervix, uterus, Fallopian tubes and the outer 
lining of the ovaries. The Wolffian ducts become the seminal 
vesicles, vasa deferens and epididymides. These ductal systems 
grow adjacent to but independent of one another. Once the 
genetic sex of the embryo becomes known specific changes 
begin to occur. For example, at about 10 weeks gestation in 
human the undifferentiated gonads become either testes, 
under the control of the SRY gene [1] or ovaries. As gonads 
begin to differentiate one of the reproductive tract primordia 
is destroyed and the other proliferates and differentiates. In fe-
males, the lack of testosterone is sufficient to allow the Wolff-
ian ducts to atrophy while in males the ablation of the Mül-
lerian duct is more complex. The French anatomist Dr. Alfred 
Jost shed some very important light on the process in males 
over 65 years ago [2,3]. At that time it was believed that the 
key to normal prenatal sexual development was whether tes-
tes were present. The testosterone they secrete would both 
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Müllerian inhibiting substance (MIS), also called anti-Müllerian hormone (AMH), is a member of the transforming 
growth factor-β super-family of growth and differentiation response modifiers. It is produced in immature Sertoli 
cells in male embryos and binds to MIS/AMH receptors in primordial Müllerian ducts to cause regression of female 
reproductive structures that are the precursors to the fallopian tubes, the surface epithelium of the ovaries, the 
uterus, the cervix, and the upper third of the vagina. Because most gynecologic tumors originate from Müllerian duct-
derived tissues, and since MIS/AMH causes regression of the Müllerian duct in male embryos, it is expected to inhibit 
the growth of gynecologic tumors. Purified recombinant human MIS/AMH causes growth inhibition of epithelial 
ovarian cancer cells and cell lines in vitro and in vitro via MIS receptor-mediated mechanism. Furthermore, several lines 
of evidence suggest that MIS/AMH inhibits proliferation in tissues and cell lines of other MIS/AMH receptor-expressing 
gynecologic tumors such as cervical, endometrial, breast, and in endometriosis as well. These findings indicate 
that bioactive MIS/AMH recombinant protein should be tested in patients against tumors expressing the MIS/AMH 
receptor complex, perhaps beginning with ovarian cancer because it has the worst prognosis. The molecular tools 
to identify MIS/AMH receptor expressing ovarian and other cancers are in place, thus, it is possible to select patients 
for treatment. An MIS/AMH ELISA exists to follow administered doses of MIS/AMH, as well. Clinical trials await the 
production of sufficient supplies of qualified recombinant human MIS/AMH for this purpose
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stimulate the Wolffian ducts and destroy the Müllerian ducts. 
Professor Jost’s experiments proved that testosterone alone 
was insufficient to the task because the gonadectomized em-
bryos he treated with testosterone crystals had retained uteri 
at birth. He proposed that a “Müllerian inhibiting substance 
(MIS)” now also called anti-Müllerian hormone (AMH), is se-
creted from the newly formed testes and that it is the MIS/
AMH which causes the regression of the Müllerian ducts. It 
was later shown that regression is due mainly to apoptosis, 
autophagocytosis, disruption of basement membranes, and 
epithelial mesenchymal transformation of cells followed by 
migration of some of the cells toward the mesonephros [4-9].
Müllerian inhibiting substance/anti-
Müllerian hormone protein
Over two decades after professor Jost’s observation the source 
of MIS/AMH in males was identified as the Sertoli cells [10,11] 
in rat [12], bovine [13,14] and human testis [15,16]. In addi-
tion, it was learned that MIS/AMH production is sexually di-
morphic. MIS/AMH gene transcription is regulated in males by 
a number of factors including SF1, SOX 9 and WT-1 in utero 
but after birth androgens have been implicated in suppression 
of MIS/AMH expression [17-23] while there are data showing 
MIS/AMH can inhibit androgen synthesis as well [24-26]. MIS/
AMH is expressed in significant amounts only by males during 
fetal life but postnatally, both granulosa cells in the female and 
Sertoli cells in the male secrete MIS/AMH. In males serum MIS/
AMH levels remain high until puberty, dropping to basal levels, 
thereafter. Although MIS/AMH mRNA is detectable in ovaries 
shortly after birth [27] MIS/AMH is undetectable in serum until 
puberty where its levels reach those of adult males (Fig. 1) 
[28]. The detection of MIS/AMH in both sexes after birth [29-
31] suggested multifunctional roles for MIS/AMH. In females, 
MIS/AMH blocks meiosis II [32], inhibits ovarian granulosa cell 
division and progesterone production [33], and modulates 
follicular development [34]. Furthermore, MIS/AMH levels in 
follicular fluid are inversely correlated with granulosa cell pro-
liferative index [35,36]. In males, MIS/AMH affects Leydig cell 
development and inhibits transcription of the steroidogenic 
enzyme, CYP17 [24,25,37,38]. Its stage-specific expression in 
seminiferous tubules implies a role in spermatogenesis [39]. 
Recent findings showing MIS/AMH and its receptor expres-
sion in pituitary and motor neurons indicate even more wide-
spread non-Müllerian roles for MIS/AMH [40,41]. In fact, the 
prostate [42,43], mammary gland [44,45] and some of their 
cancers [45,46] as well as ocular melanoma [47] are possible 
targets for MIS/AMH. The role MIS/AMH plays in these tissues 
is at present unknown. 
MIS/AMH was purified from testicular secretions in vitro 
[13,48,49] or protein extracts [13,50-56] by conventional 
biochemical techniques [13,48-56] and compositional analy-
ses revealed it to be a 140 kDa glycoprotein disulfide linked 
homo-dimer of approximately 15% carbohydrate by weight. 
MIS/AMH is cleaved into two fragments, most likely during 
the biosynthetic process before secretion by kex-like prohor-
mone convertases. 
Analyses of bovine cDNA and human genomic sequences 
revealed MIS/AMH to be weakly related to the transforming 
beta family of proteins with the most striking homology (28%) 
residing in the carboxy-terminal domain [55,56]. The 2.8 kb 
human gene contains five exons and four introns and is lo-
cated on the short arm of chromosome 19 [57]. The deduced 
protein sequence of the MIS/AMH monomer contains a 25 
amino acid secretion specific signal peptide and a monomeric 
protein of 535 amino acids that, when glycosylated at two 
glycosylation sites, has a molecular weight of 70 kDa (Fig. 2) 
[28]. Lysis at a protease cleavage motif at amino acid residue 
427 explains the origin of the major MIS/AMH fragments (55 
kDa amino-terminus and 12.5 kDa carboxy-terminus) appear-
ing on reduced polyacrylamide gels of the purified protein. A 
weaker motif at residue 229 is also present but its role in MIS/
AMH action is unclear. In the native molecule it is the carboxy-
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Fig. 1. MIS Expression is sexually dimorphic helpful in assessing of Intersex 
and gonadal tumor patients. Serum Müllerian inhibiting substance (MIS)/anti-
Müllerian hormone (AMH) in humans varies with sex and age. MIS/AMH in 
males is high at birth and levels are maintained until puberty. MIS/AMH in fe-
males becomes measurable at puberty and is gone by the menopause. Elevated 
MIS in females (dashed line) is consistent with granulosa/sex cord tumors. MIS 
levels drop in response to therapy (Reproduced from MacLaughlin DT, et al. 
Future Oncol 2010;6:391-405, with permission of Future Medicine Ltd.) [28].www.ogscience.org 345
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terminal disulfide linked homodimer (25 kDa), which possess-
es the biological activity [58-60]. The amino-terminal domain 
may contribute to proper protein folding and assembly dur-
ing synthesis and/or it may increase the serum half-life of the 
carboxy-terminus and enhance bioactivity [59]. The carboxy-
terminal sequence of MIS/AMH is extremely highly conserved, 
a fact that explains why MIS/AMH from many different spe-
cies are all active in the rat in vitro bioassay used for MIS/AMH 
purification. The human gene was transfected into Chinese 
hamster ovary (CHO) cells and its conditioned medium is used 
as a source of recombinant human MIS/AMH [61,62] for pu-
rification of the MIS/AMH needed for all of our studies. The 
MIS/AMH as purified from serum free conditioned media is 
proteolytically processed by endogenous CHO enzymes, it is 
free of contaminants from bovine serum, hamster cells, and 
the mouse monoclonal antibody used to purify it [62], and 
significant amounts of endotoxins [45].
Müllerian inhibiting substance/anti-
Müllerian hormone receptors
MIS/AMH biological activity requires interaction with two 
similar but distinct receptors termed type I and II. These single 
membrane spanning, serine-threonine kinases cross phos-
phorylate upon MIS/AMH binding and initiate intracellular cas-
cades that lead to the control of cell cycle regulating proteins 
and altered transcription of a number of genes, depending 
upon the target tissues. The type II receptor binds the ligand 
and the type I heteromer is the signaling receptor (Fig. 3) [28]. 
The MIS/AMH type II receptor was cloned in the laboratories 
of Baarends and Themmen, Josso and Cate, and Behringer, 
as well as our own laboratory [63-66]. The human gene is 
located on chromosome 12q13 [67] and has 11 exons and 10 
introns.
The MIS/AMH type II receptor is expressed in Müllerian duct 
mesenchyme around the adjacent ductal epithelium, consis-
tent with the fact that the fetal mesenchyme directs Müllerian 
duct regression [63-65]. The receptor is also found in fetal 
and adult Leydig and granulosa cells [38,39,68,69] where it 
regulates testosterone [24,38,39,68], estradiol and progester-
one synthesis [69]. The MIS/AMH type II receptor is made by 
rodent uteri [66,70], human endometrium [70], breast and 
prostate tissues [42,44] and, surprisingly, in motor neurons in 
the mouse brain [41]. It is not yet understood what MIS/AMH 
is doing to these tissues but MIS/AMH inhibits the prolifera-
tion of tumor cell lines derived from them supporting our hy-
pothesis that MIS/AMH may be a useful adjuvant agent in the 
treatment of these diseases. 
Persistent Müllerian duct syndrome results from loss of func-
tion mutations in the MIS/AMH type II receptor and/or the 
MIS/AMH molecule itself [71]. A common mutation in the 
MIS/AMH gene deletes the carboxy-terminal domain and is 
therefore, it fails to regress the Müllerian duct. Heterozygotes 
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Fig. 2. The human Müllerian inhibiting substance (MIS)/anti-Müllerian 
hormone (AMH) gene has 5 exons and 4 introns and encodes a 70 kDa 
monomer with two N-linked glycosylation sites (circles). The disulfide-linked 
homodimer is activated by biosynthetic proteases to produce the 25-kDa 
carboxy-terminal dimer. This domain is responsible for its bioactivity. The 
110-kDa amino-terminus stays associated with the carboxy-terminus via 
non-covalent forces (Reproduced from MacLaughlin DT, et al. Future Oncol 
2010;6:391-405, with permission of Future Medicine Ltd.) [28].
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Fig. 3. MIS signals via a heteromeric receptor system. The human Müllerian 
inhibiting substance (MIS)/anti-Müllerian hormone (AMH) type II receptor gene 
has 11 exons and the type I gene has 9. They share several features including 
extracellular ligand-binding domains, transmembrane spanning regions and 
intracellular serine-threonine kinase domains. Both types are required for MIS/
AMH signaling and mutations in the type II receptor are associated with phe-
notypic changes in humans (Reproduced from MacLaughlin DT, et al. Future 
Oncol 2010;6:391-405, with permission of Future Medicine Ltd.) [28].www.ogscience.org 346
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of either mutation type, i.e. receptor or ligand have normal 
phenotypes; affected individuals are either homozygous for a 
given mutation or compound heterozygotes. Recently, a new 
intron mutation associated with Persistent Müllerian duct syn-
drome has been identified, as well [72].
Several different type I receptors (Alk2, Alk3, and Alk6) have 
been identified as interacting with the type II receptor [73-78]. 
How each type I receptor interacts with the type II receptor in 
human tissues is not know although all are expressed in the 
human cancer cell lines studied.
Serum Müllerian inhibiting substance/
anti-Müllerian hormone clinical utility
The discovery that males and females both express MIS/AMH 
postnatally prompted numerous studies which revealed the 
usefulness of measuring MIS/AMH in serum in a variety of 
clinical situations including ambiguous genitalia, undescended 
testes, delayed puberty, sex cord and granulosa cell tumors. 
Fortunately, three very useful human MIS/AMH-specific and 
highly sensitive immunoassays were developed concurrently 
by the Donahoe, Josso and Hutson laboratories [29-31] for 
this purpose and several are commercially available thus, im-
pacting the practice of pediatric endocrinology, pediatric sur-
gery and gynecologic oncology [29-31].
Serum MIS/AMH, is a strong predictor of the presence of 
testicular tissue when testes are not palpable [79]. It also is a 
useful indicator of testis function in these cases and in cases of 
sexual ambiguity. Normal MIS/AMH levels are consistent with 
normal testes, undetectable MIS/AMH reflects absent testes 
whereas, low MIS/AMH is often due to gonadal dysgenesis. 
Serum MIS/AMH data can be more useful than hCG stimula-
tion tests to evaluate gonadal status.
Serum MIS/AMH correlates with ovarian reserve and it is an 
indicator of response to in vitro fertilization protocols [36,80-
85]. The vast majority of sex cord and granulosa cell tumors 
[86,87] secrete MIS/AMH in proportion to tumor burden [88] 
and changes in serum MIS/AMH reflect recurrences and/or 
response to therapy. These tumors may express the MIS/AMH 
receptor [89] but the tumors are not responsive to the MIS/
AMH they produce. This fact implies a loss of function down-
stream from the receptor itself, therefore, these tumors are 
not considered targets for MIS/AMH therapy. Serum concen-
trations of MIS/AMH above the normal for age is consistent 
with the presence of either one of these tumors; rising serum 
MIS/AMH reflects tumor growth and decreases show response 
to therapy [86]. MIS/AMH levels can reach thousands fold the 
normal range without any adverse reactions that could be at-
tributed to the MIS/AMH molecule. It is for this reason that 
we predict that MIS/AMH administered to cancer patients as a 
may have a very favorable toxicity profile (see below). Wheth-
er recombinant human MIS/AMH is toxic will be the topic of 
detailed toxicology studies planned for the future when clini-
cal grade MIS/AMH is available.
Müllerian inhibiting substance/anti-
Müllerian hormone and cancer therapy
Much of the research effort has focused the molecular mecha-
nism of action of MIS/AMH [90-93]. A major goal of this work 
is to translate findings into new therapies or diagnostic tools 
for the management of pediatric diseases requiring medical 
intervention and/or surgical reconstruction. In addition to the 
clinical uses of MIS/AMH measurements listed above, an unex-
pected consequence of the knowledge gained form basic MIS/
AMH research is the use of recombinant human MIS/AMH as 
a novel, naturally occurring, potentially nontoxic, cancer drug 
administered to patients with MIS/AMH receptor expressing 
malignancies. 
As it became clear that MIS/AMH inhibits cell division and/
or induces apoptosis in a highly specific manner, it was sug-
gested by a colleague of ours, Professor Robert Scully of the 
Massachusetts General Hospital Pathology Department and an 
expert in ovarian cancer, that MIS/AMH might be an inhibitor 
of cancers of Müllerian duct origin. His observation that epi-
thelial ovarian cancers recapitulate embryonic Müllerian histol-
ogy [94], lead to the logical question of whether these lesions 
could be MIS/AMH targets. If so, administration of exogenous 
MIS/AMH could be an effective, highly specific reagent to in-
clude in existing treatments for epithelial ovarian cancer [95-
99]. Results of more recent experiments, however, identify 
cervical and endometrial cancers as other potential targets 
[70,100], as well as several non-Müllerian cancers, including 
breast [43,45,46], prostate [43] and ocular melanoma [47] 
(see below). Our original hypothesis, therefore, is extended to 
include any tumor that expresses a functional MIS/AMH type 
II receptor. After examining a considerable body of pre-clinical 
experimental results we conclude that MIS/AMH may indeed 
be a useful cancer drug and we propose that phase I trials be 
initiated as soon as sufficient clinical grade material is avail-www.ogscience.org 347
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able. 
The concept that a naturally occurring growth inhibitor such 
as MIS/AMH could be an effective adjuvant treatment for can-
cer is attractive because MIS/AMH type II receptor expression 
is restricted to so few tissues thus minimizing the potential for 
adverse side effects. For the same reason, MIS/AMH may be 
used as a delivery system for more toxic drugs, again limiting 
exposure to non-target tissues. Our choice to focus initially on 
certain of the ovarian cancers arises from the fact that they 
have, when compared with other potential MIS/AMH targets, 
the worst prognosis and might benefit significantly from this 
novel biological reagent, thus offering a new approach to 
augment the efforts of others to find useful new strategies to 
employ.
1.   Müllerian inhibiting substance/anti-Müllerian hormone 
 and ovarian cancer
Validating MIS/AMH as an anti-cancer drug particularly for 
ovarian cancers has been the focus of our laboratory since we 
first hypothesized that any cancer of Müllerian origin could be 
a target for MIS/AMH treatment [95,96]. The notion that MIS/
AMH could be used to treat ovarian cancer is predicted by 
the fact that the histology of the embryonic Müllerian ducts 
is somewhat reproduced in the common ovarian adenocarci-
nomas that can arise from the outer ovarian coelomic epithe-
lium. 
Epithelial ovarian cancer affects nearly 25,000 North 
American women each year and is the fifth most common 
malignancy in women with a five-year mortality of over 70% 
[101]. The mortality rate is significantly lower in stage Ia or Ib 
disease, but early peritoneal seeding and metastatic spread 
accounts for the fact that less than 25% of women are diag-
nosed with early stage disease. Combined surgery and cyto-
toxic therapy produce favorable clinical responses in 50% to 
80% of patients but, unfortunately, the majority of patients 
relapse, therefore, it is timely to search for novel therapies for 
ovarian cancer [99,102].
Our hypothesis was supported by results of initial in vitro 
studies using human ovarian cancer cell lines [96,103-105] or 
tissues [106] followed by a series of ex-vivo experiments with 
human cancer cell lines [98]. Studies were also conducted on 
ovarian cancer cells in ascites specimens harvested collected 
from patients with new or recurrent disease [97]. Importantly, 
over 50% of the stage III ovarian patients had cells that bound 
recombinant human MIS/AMH, expressed the MIS/AMH type 
II receptor, and were growth inhibited by MIS/AMH [97]. Two 
other more recent studies corroborate and extend these find-
ings on the incidence of receptor expression in benign and 
malignant cancers of Müllerian origin [107,108]. Therefore, 
the incidence of MIS/AMH responsive cases is sufficiently high 
to warrant further clinical investigation. The observations on 
fresh surgical specimens and ascitic fluid, however, are per-
haps the most significant to date as they reflect what is true 
for patients and not cell lines. Receptor expression is frequent 
in a random sample of ovarian cancer cases and the receptor 
appears to be functional as MIS/AMH inhibits cancer cell pro-
liferation in vitro [97].
The pre-clinical studies of MIS/AMH in ovarian cancer were 
advanced greatly by the development of a new mouse model 
by Dr. Connolly and colleagues at the Fox Chase Cancer 
Center [109]. These tumors appear very similar to the phe-
notype of the most common human ovarian cancer, serous 
cystadenocarcinoma with a relatively large percentage (50%) 
of mice developing cancers within a few months of birth. Cell 
lines from these tumors, called MOVCAR cells, express the 
MIS/AMH type II receptor mRNA, they grew rapidly in culture, 
and they respond to MIS/AMH in vitro in a dose dependent 
manner with up to 95% growth inhibition (Fig. 4) [110]. To 
study the effects of MIS/AMH in vivo, nude mice were injected 
in the leg or into the dorsal fat pad with MOVCAR tumor cells 
at six weeks of age. Tumors appeared in a dose dependent 
manner in both implantation sites. When 10,000 cells were 
injected tumors appeared in approximately ten weeks. By 
comparison, 100,000 cells produced tumors in eight weeks, 
and tumors were visible in nine weeks after injection of 3×106 
cells, and 12×106 cells produced tumors in approximately four 
weeks. Intraperitoneal injection of the animals with MIS/AMH 
lengthened the time to tumor appearance and tumor volume 
significantly smaller (Fig. 5). No apparent toxicity was detected 
and considering the fact that this duration of MIS/AMH ex-
posure in the mouse is roughly equivalent to about 7 years 
of continuous cancer treatment in human, MIS/AMH may be 
relatively safe. In a preliminary experiment, a MOVCAR tumor 
was allowed to grow for over 20 weeks in the fat-pad before 
MIS/AMH treatment. The tumor completed regressed after 5 
weeks of treatment days of treatment (Fig. 6) [111]. The buf-
fer control treated animal’s tumor continued to grow.
After phase I trials are completed MIS/AMH will most likely 
be administered to patients in simultaneously with other 
drugs. It was important, therefore, to study potential inter-
actions between MIS/AMH and commonly used cytotoxic 
agents. Mechanism of action studies thus far show that MIS/www.ogscience.org 348
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AMH downstream signal transduction pathways include 
Smads, cyclin dependent kinase inhibitors, and cytokine induc-
ible pathways. MIS/AMH also increased expression of p16, an 
inhibitor of cell cycle progression, the pocket proteins p107, 
and p130 as well as the apoptosis associated-E2F1 protein 
[105]. Another study reported last year has identified a num-
ber of other genes that are up and down regulated by MIS/
AMH in an ovarian cancer cell line [112]. These results suggest 
MIS/AMH mechanisms of action very different from those 
of targeted by most chemotherapeutic agents. If MIS/AMH 
and drugs can function in combination it may be possible to 
decrease the dose needed for either agent alone, potentially 
resulting in decreased toxicity. In fact, preliminary studies with 
epithelial ovarian cancers in vitro demonstrated that combina-
tion therapy with MIS/AMH may indeed provide a means of 
reducing toxicity while maintaining or enhancing clinical effec-
tiveness (Fig. 7) [113]. Using MOVCAR cells from the murine 
model dose responses to rapamycin, and three ovarian cancer 
chemotherapeutic drugs paclitaxel, cisplatin, and doxorubicin 
were established and the effect of added recombinant human 
MIS/AMH determined. These studied showed that rapamycin 
and MIS/AMH were synergistic; MIS/AMH and paclitaxel were 
additive; MIS/AMH and cisplatin were additive; and the com-
bination of doxorubicin and MIS/AMH was synergistic. 
The ultimate translation of MIS/AMH as a therapeutic, from 
studies on cancers in vitro, to preclinical trials in animals, and 
eventually to phase I clinical trials, means sufficient quantities 
of clinical grade recombinant human MIS/AMH need to be 
produced. Accordingly, our laboratory has spent considerable 
effort optimizing purification protocols from mammalian cells 
and is exploring a number of alternative sources for enhanced 
production of MIS/AMH. In addition, we have developed MIS/
MOVCAR cells: dorsal fat pad
Movcar cells: left posterior leg
A
B
V
o
l
u
m
e
 
(
m
m
3
)
V
o
l
u
m
e
 
(
m
m
3
)
1,200
2,000
1,500
1,000
500
0
1,000
800
600
400
200
0
30 40
35 47 57 62 70 76 82
50 60
PBS
MIS
70 80
Days post MOVCAR cell injection
Days post MOVCAR cell injection
PBS
MIS
*
*
*
* *
*
*
* *
*
*
*
*
Fig. 5. Recombinant human Müllerian inhibiting substance (MIS)/anti-
Müllerian hormone (AMH) decreases growth of MOVCAR allografts in nude 
mice. Cells were injected in the dorsal fat pad (A) or the left leg (B) and 
animals treated with PBS or MIS/AMH. Tumor volumes (+/- SEM) 35 to 82 
days after injection are shown (From Pieretti-Vanmarcke R, et al. Clin Can-
cer Res 2006;12:1593-8, with permission from American Association for 
Cancer Research) [110]. *Significant from control. 
Movcar dose response to MIS
Movcar growth: MIS vs. control
A
B
%
 
G
r
o
w
t
h
O
D
 
(
n
m
)
120
100
80
60
40
20
0
0
0.4
0.8
    1.2
1.6
2
0 2
Dose (μg/mL)
P<0.000001
Treatment
Control MIS
4 6 8 10
Fig. 4. Recombinant human Müllerian inhibiting substance (MIS)/anti-
Müllerian hormone (AMH) inhibits MOVCAR cell lines in vitro in a dose 
dependent manner (A). (B) shows the mean level of inhibition of MOVCAR 
cells by 71 nM MIS/AMH in six different experiments; approximately 95% 
compared to controls in a colorimetric cell count assay (From Pieretti-
Vanmarcke R, et al. Clin Cancer Res 2006;12:1593-8, with permission from 
American Association for Cancer Research) [110].www.ogscience.org 349
Jang Heub Kim, et al. MIS/AMH: A novel treatment for Müllerian tumors
AMH-specific assays to detect the protein and measure its bio-
activity with a high degree of precision.
2.   Müllerian inhibiting substance/anti-Müllerian hormone   
 and other Müllerian tissues and cancers
Normal cervix and cervical tumors express the MIS/AMH type 
II receptor protein by immunohistochemistry and mRNA by RT-
PCR (Fig. 8) [100]. Human cervical cancer cell lines respond to 
MIS/AMH. Three human cervical carcinoma cell lines, CaSki, 
SiHa, and C33A were all growth inhibited in vitro by MIS/AMH 
added to the growth media or MIS/AMH produced by the 
cells themselves after transient transfection with a transcript 
encoding bioactive MIS/AMH (Fig. 9) [114]. As is true of ovar-
ian cancer cell lines MIS/AMH upregulated p16, p130, p107, 
E2F1 in the C33A cell line. Interestingly, overexpression of 
p16, p130, p107, or E2F1 inhibited cell growth compared to 
vectors alone [100]. These findings in cervical cancer further 
broaden the targets for MIS/AMH.
In addition to the cervix, Fallopian tubes, and the ovarian lin-
ing, the uterus is also a Müllerian structure. The MIS/AMH type 
II receptor mRNA is expressed in the Müllerian ducts of the fe-
male rat embryo between days 13 and 19 of development and 
in the uterine mesenchyme during the first postnatal days. The 
MIS/AMH type II receptor protein was also detected in a human 
endometrial cancer cell line AN3CA [70] and normal and preg-
nant adult rat uterus by western analysis [70] but not in small 
intestine (Fig. 10) [70]. In the human, MIS/AMH type II receptor 
mRNA was detected in myometrium and endometrium of a 
Fig. 7. In vitro dose responses for MOVCAR7 cells for Müllerian inhibiting substance (MIS)/anti-Müllerian hormone (AMH) and rapamycin, paclitaxel, 
cisplatin and doxorubicin alone (A-E) and results of combination treatments (bar graphs, bottom) are shown. Rapamycin and doxorubicin were synergistic 
with MIS/AMH Ⓢ; Paclitaxel and cisplatin were additive Ⓐ. Significant inhibition relative to controls is indicated by an asterisk (*); MIS/AMH alone was 
always significantly different from combination treatment (**) (From Pieretti-Vanmarcke R, et al. Proc Natl Acad Sci U S A 2006;103:17426-31, with per-
mission from National Academy of Sciences) [113].
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Fig. 6. Müllerian inhibiting substance (MIS)/anti-Müllerian hormone given 
intraperitoneally for 38 days to a mouse after a dorsal fat pad tumor had 
formed ablated the mass. (A) shows the treated animal (top) and the con-
trol animal (bottom) with its tumor (arrow). Tumor volume measurements 
are given in (B) (From Jakowlew SB, editor. Transforming growth factor-
[beta] in cancer therapy. 1st ed. Totowa: Humana Press; 2008, with permis-
sion from Springer ) [111].www.ogscience.org 350
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post-menopausal uterus and the protein observed by western 
analysis in endometrial tumors. Two cancer cell lines which 
express the receptor mRNA and protein were inhibited by MIS/
AMH as well (Fig. 11) [70]. AN3CA, an endometrial carcinoma 
metastasis, showed significant growth inhibition (57% to 67% 
inhibition relative to control, 0%). KLE, a human cell line de-
rived from a poorly differentiated endometrial cancer, also dem-
onstrated significant growth inhibition (44.9%) after treatment 
with MIS/AMH. The cervical and endometrial transfection data 
support the conclusion that the growth inhibition effects are 
due to the MIS/AMH molecule itself rather than a contaminant 
in the purified protein preparation. Unlike the ovarian and cervi-
cal cancer cell lines AN3CA cells do not express p16 or p21 but 
MIS/AMH does induce p107, p130 and E2F1 [70].
3.   Müllerian inhibiting substance/anti-Müllerian 
hormone and non-Müllerian tissues and cancers
It is noteworthy that MIS/AMH type II receptor is expressed 
in locations other than Müllerian tissues and gonads. In ad-
Fig. 8. (A) Inhibition of cervical cancer cell growth by Müllerian inhibiting 
substance (MIS)/anti-Müllerian hormone (AMH) for C33A and CaSki cells, after 
4 days of MIS/AMH treatment (P<0.001). (B) C33A cells stably transfected 
with empty vector, an inactive MIS/AMH (K1), or bioactive MIS/AMH (K2). K1 
had little effect, whereas active MIS/AMH inhibited to over 90% (From Barbie 
TU, et al. Proc Natl Acad Sci U S A 2003;100:15601-6, with permission from 
National Academy of Sciences) [100].
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Fig. 9. RT-PCR of Müllerian inhibiting substance type II receptor mRNA from 
human cervix and cervical cancers. Bands of 361 bp are detected in normal 
cervix (a,b), squamous cell carcinoma of cervix (c), and adenocarcinoma of cer-
vix (d). Lane (e) is the DNA ladder [114].
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Fig. 10. Müllerian inhibiting substance/anti-Müllerian hormone type II recep-
tor protein expression in the rat uterus. Pregnant (A) and non-pregnant (B) 
uteri and ovary are positive for the receptor but not intestine by western assay. 
Receptor expression may increase with pregnancy (From Renaud EJ, et al. Proc 
Natl Acad Sci U S A 2005;102:111-6, with permission from National Academy 
of Sciences) [70].
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Fig. 11. 71 nM recombinant human Müllerian inhibiting substance (MIS)/
anti-Müllerian hormone (AMH) significantly inhibits proliferation of human en-
dometrial cancer cell lines AN3CA (by 67%) and KLE (by 52%) compared with 
cells treated with buffer control. MIS/AMH did not inhibit the growth of COS 7 
cells, which do not express the MIS/AMH type II receptor (From Renaud EJ, et 
al. Proc Natl Acad Sci U S A 2005;102:111-6, with permission from National 
Academy of Sciences) [70].www.ogscience.org 351
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dition to the ocular melanoma already mentioned, MIS/AMH 
type II receptor is expressed in motor neurons [41] and the 
normal rat breast epithelium at levels inversely proportional to 
the state of proliferation of the tissue [44]. In several estrogen 
receptor positive and negative human breast cancer cell lines 
MIS/AMH enhanced IĸB dependent DNA binding of NFĸB that 
resulted in induction of IEX-1 mRNA [44], an immediate early 
gene induced by radiation, interferon γ , or tumor necrosis 
factor alpha but not by TGFβ [45,116,117]. Apoptosis was 
enhanced in the mammary epithelium of MIS/AMH injected 
animals compared to control animals [44], therefore, breast 
cancer could well be another target for MIS/AMH therapy. 
MIS/AMH treatment of cancer may also include the prostate 
[42,43]. The MIS/AMH type II receptor and two candidate MIS/
AMH type I receptors [74-78] are expressed in a prostatic can-
cer cell line (LNCaP) as well as in human prostate tumors [42]. 
MIS/AMH blocks the growth of human prostate cancer cell 
lines and it induces IRF1, and interferon γ  was that enhances 
the inhibiting effects of MIS/AMH in vitro and in vivo. Further-
more, because MIS/AMH suppresses testosterone production 
[13,37-39] it might indeed exert a double effect on prostatic 
cancer, a direct growth inhibition and an indirect effect by 
lowering testosterone. 
Müllerian inhibiting substance/anti-
Müllerian hormone and endometriosis
Endometriosis is a common benign disease of reproductive 
women, especially infertile women. Ectopic endometrial cells 
exhibit abnormal proliferative and apoptotic regulation in endo-
metriosis. Recent reports show that MIS induces the cell cycle 
arrest and apoptosis of human endometrial stromal cells and 
endometriosis cell line in vitro. One study shows that the cel-
luar apoptosis was increased by causing arrest at G1 phase and 
increasing cells at sub-G0G1 phase in endometrial stromal cells 
treated with MIS for 72 hours (Fig. 12) [118]. Another study 
shows that MIS induces autophagy through increased expres-
sion of Beclin-1 autophagy-promoting protein in endometriosis 
cell line [119]. These findings suggest that MIS play an impor-
tant role in cellular apoptosis in endometriosis. Therefore, MIS 
has a potential as a therapeutic modalities in endometriosis.
Conclusion
The existing literature on MIS/AMH suggests that the recom-
binant human protein will have very little toxicity in vivo and 
that it should be tested against tumors expressing the MIS/
AMH type II receptor, perhaps beginning with ovarian cancer 
as among receptor expressing tumors, since it has the most 
dire prognosis. The molecular tools to identify MIS/AMH re-
ceptor expressing ovarian and gynecologic tumors are already 
in hand, thus, it is possible to select patients for treatment. An 
MIS/AMH ELISA exists to follow administered doses of MIS/
AMH, as well. Clinical trials await the production of sufficient 
supplies of recombinant human MIS/AMH for this purpose.
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